Merck KGaA earmarks $855M for Debiopharm's programmed cell death promoting drug in global licensing deal
Merck KGaA, primarily known for its CDMO work, is playing with giants in oncology and looking at novel mechanisms of action to compete. Now, the German player is placing a big down payment on a late-stage candidate looking to stop tumor cells’ ability to stave off programmed death.
Merck KGaA will dole out $226 million upfront and up to $855 million in future milestones and royalty payments for exclusive rights to Debiopharm’s IAP candidate xevinapant, which recently emerged from Phase II in first-line, non-metastatic squamous cell carcinoma of the head and neck, the German firm said Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
